Pyrrolobenzodiazepines
View Patent ↗A compound with the formula I: wherein: R 2 is of formula II: where A is a C 5-7 aryl group, X is selected from the group comprising: NHNH 2 , CONHNH 2 , formula III, formula IV, and either: (i) Q 1 is a single bond, and Q 2 is selected from a single bond and —Z—(CH 2 ) n —, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q 1 is —CH═CH—, and Q 2 is a single bond; R 12 is a C 5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene; R 6 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; where R and R′ are independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups; R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR′, nitro, Me 3 Sn and halo; either: (a) R 10 is H, and R 11 is OH, OR A , where R A is C 1-4 alkyl; (b) R 10 and R 11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R 10 is H and R 11 is SO z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R″ is a C 3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, and/or aromatic rings; Y and Y′ are selected from O, S, or NH; R 6′ , R 7′ , R 9′ are selected from the same groups as R 6 , R 7 and R 9 respectively and R 10′ and R 11′ are the same as R 10 and R 11 , wherein if R 11 and R 11′ are SO z M, M may represent a divalent pharmaceutically acceptable cation.
1. A compound with the formula I:
wherein:
R 2 is of formula II:
where A is phenyl, naphthyl or a C 5-7 heteroaryl group, X is selected from the group consisting of: NHNH 2 , CONHNH 2 ,
and either:
(i) Q 1 is a single bond, and Q 2 is selected from a single bond and —Z—(CH 2 ) n —, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or
(ii) Q 1 is —CH═CH—, and Q 2 is a single bond;
R 12 is a phenyl, naphthyl, or C 5-10 heteroaryl group, optionally substituted by one or more substituents selected from the group consisting of: halo, nitro, cyano, C 1-7 alkoxy, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene;
R 6 and R 9 are H;
R 7 is a C 1-4 alkoxy, optionally substituted by a C 5 heteroaryl or phenyl group either:
(a) R 10 is H, and R 11 is OH, OR A , where R A is C 1-4 alkyl;
(b) R 10 and R 11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or
(c) R 10 is H and R 11 is SO z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;
R″ is a C 3-12 alkylene group, which chain may be interrupted by one or more aromatic rings;
Y and Y′ are selected from O, S, and NH;
R 6′ , R 7′ , R 9′ are selected from the same groups as R 6 , R 7 and R 9 respectively and R 10′ and R 11′ are the same as R 10 and R 11 , wherein if R 11 and R 11′ are SO z M, M may represent a divalent pharmaceutically acceptable cation,
wherein the term C 3-7 heterocyclyl refers to a monovalent moiety obtained by removing a hydrogen atom for a ring atom of a heterocyclic compounds which has from 3 to 7 ring atoms of which 1 to 4 are ring heteroatoms selected from N, O and S,
wherein the term C 5-10 heteroaryl refers to a monovalent moiety obtained by removing a hydrogen atom for a ring atom of a heteroaromatic compound which has from 5 to 10 ring atoms of which 1 to 4 are ring heteroatoms selected from N, O and S.
2. A compound according to claim 1 , wherein Y is O, and R″ is C 3-7 alkylene.
3. A compound according to claim 1 , wherein A is phenyl, and X is selected from:
(a) and
(b) NHNH 2 and CONHNH 2 .
4. A compound according to claim 1 , wherein Q 1 is a single bond; and Q 2 is:
(a) a single bond; or
(b) —Z—(CH 2 ) n —, Z is O or S and n is 1 or 2.
5. A compound according to claim 1 , wherein R 2 is -A-X, and X is
6. A compound according to claim 1 , wherein R 12 is phenyl, which bears one to three substituent groups, selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl.
7. A compound according to claim 1 , wherein R 6′ , R 7′ , R 9′ , R 10′ , R 11″ and Y′ are the same as R 6 , R 7 , R 9 , R 10 , R 11 and Y respectively.
8. A compound of formula II:
wherein:
R 2 is of formula II:
where A is phenyl or a C 5-7 heteroaryl group, X is selected from the group consisting of: NHNH 2 , CONHNH 2 ,
and either:
(i) Q 1 is a single bond, and Q 2 is selected from a single bond and —Z—(CH 2 ) n —, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or
(ii) Q 1 is —CH═CH—, and Q 2 is a single bond;
R 12 is phenyl, naphthyl or a C 5-10 heteroaryl group, optionally substituted by one or more substituents selected from the group consisting of: halo, nitro, cyano, C 1-7 alkoxy, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene;
R 6 and R 9 are H;
R 7 is a C 1-4 alkoxy, optionally substituted by a C 5 heteroaryl or phenyl group;
R″ is a C 3-12 alkylene group, which chain may be interrupted by one or more aromatic rings;
Y and Y′ are selected from O, S, and NH;
R 6′ , R 7′ , R 9′ are selected from the same groups as R 6 , R 7 and R 9 respectively and R 10′ and R 11′ are the same as R 10 and R 11 , wherein if R 11 and R 11′ are SO z M, M may represent a divalent pharmaceutically acceptable cation;
and either:
(a) R 10 is carbamate nitrogen protecting group, and R 11 is O-Prot O , wherein Prot O is an oxygen protecting group;
(b) R 10 is a hemi-aminal nitrogen protecting group and R 11 is an oxo group;
and R 10′ and R 11′ are the same as R 10 and R 11 ,
wherein the term C 3-7 heterocyclyl refers to a monovalent moiety obtained by removing a hydrogen atom for a ring atom of a heterocyclic compounds which has from 3 to 7 ring atoms of which 1 to 4 are ring heteroatoms selected from N, O and S,
wherein the term C 5-10 heteroaryl refers to a monovalent moiety obtained by removing a hydrogen atom for a ring atom of a heteroaromatic compound which has from 5 to 10 ring atoms of which 1 to 4 are ring heteroatoms selected from N, O and S.
9. A compound according to claim 8 , wherein R 10 is Troc and R 11 is OTBS.
10. A compound according to claim 8 , wherein R 11 is oxo and R 10 is SEM.
11. A Conjugate having formula III:
L-(LU-D) p (III)
wherein L is a Ligand unit selected from an antibody and an antigen-binding fragment of an antibody,
LU is a Linker unit which is A 1 -L 1 , wherein A 1 is selected from:
where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to the Ligand unit, and n is 0 to 6;
where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to the Ligand unit, and n is 0 to 6;
where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30; or
where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30;
wherein the above formulae the maleimide-derived group may be replaced by —NH—C(O)—CH 2 —; and
L 1 selected from an amino acid sequence which is cleavable by the action of an enzyme,
p is 1 to 20; and
D is a Drug unit with the formula I:
wherein:
R 2 is of formula II:
where A is phenyl, naphthyl or a C 5-7 heteroaryl group, X is selected from the group consisting of: *NHNH q , *CONHNH q ,
where * indicates where the group is bound to the PBD moiety, and q indicates where the group is bound to the Linker Unit and either:
(i) Q 1 is a single bond, and Q 2 is selected from a single bond and —Z—(CH 2 ) n —, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or
(ii) Q 1 is —CH═CH—, and Q 2 is a single bond;
R 12 is a phenyl, naphthyl, or C 5-10 heteroaryl group, optionally substituted by one or more substituents selected from the group consisting of: halo, nitro, cyano, C 1-7 alkoxy, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene;
R 6 and R 9 are H;
R 7 is a C 1-4 alkoxy, optionally substituted by a C 5 heteroaryl or phenyl group;
either:
(a) R 10 is H, and R 11 is OH, OR A , where R A is C 1-4 alkyl;
(b) R 10 and R 11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or
(c) R 10 is H and R 11 is SO z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;
R″ is a C 3-12 alkylene group, which chain may be interrupted by one or more aromatic rings;
Y and Y′ are selected from O, S, and NH;
R 6′ , R 7′ , R 9′ are selected from the same groups as R 6 , R 7 and R 9 respectively and R 10′ and R 11′ are the same as R 10 and R 11 , wherein if R 11 and R 11′ are SO z M, M may represent a divalent pharmaceutically acceptable cation,
wherein the term C 3-7 heterocyclyl refers to a monovalent moiety obtained by removing a hydrogen atom for a ring atom of a heterocyclic compounds which has from 3 to 7 ring atoms of which 1 to 4 are ring heteroatoms selected from N, O and S,
wherein the term C 5-10 heteroaryl refers to a monovalent moiety obtained by removing a hydrogen atom for a ring atom of a heteroaromatic compound which has from 5 to 10 ring atoms of which 1 to 4 are ring heteroatoms selected from N, O and S.
12. The Conjugate of claim 11 , wherein
where the asterisk indicates the point of attachment to L 1 , the wavy line indicates the point of attachment to the Ligand unit, and n is 0 to 6.
13. The Conjugate of claim 11 , wherein L 1 selected from an amino acid sequence, which is a dipeptide selected from the group consisting of valine-alanine, valine-citrulline and phenyalanine-lysine.
14. A drug linker of formula V:
LU-D (V)
or a pharmaceutically acceptable salt or solvate thereof, wherein LU is a Linker unit which is G 1 -L 1 , wherein G 1 is selected from:
where the asterisk indicates the point of attachment to L 1 and n is 0 to 6;
where the asterisk indicates the point of attachment to L 1 and n is 0 to 6;
where the asterisk indicates the point of attachment to L 1 , n is 0 or 1, and m is 0 to 30;
where the asterisk indicates the point of attachment to L 1 , n is 0 or 1, and m is 0 to 30;
and wherein the above formulae the maleimide group may be replaced by —NH—C(O)—CH 2 X, where X is Cl, Br or I,
L 1 is selected from an amino acid sequence which is cleavable by the action of an enzyme and D is a Drug unit with the formula I:
wherein:
R 2 is of formula II:
where A is phenyl, naphthyl or a C 5-7 heteroaryl group, X is selected from the group consisting of: *NHNH q , *CONHNH q ,
where * indicates where the group is bound to the PBD moiety, and q indicates where the group is bound to the Linker Unit and either:
Q 1 is a single bond, and Q 2 is selected from a single bond and —Z—(CH 2 ) n —, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or
(ii) Q 1 is —CH═CH—, and Q 2 is a single bond;
R 12 is a phenyl, naphthyl, or C 5-10 heteroaryl group, optionally substituted by one or more substituents selected from the group consisting of: halo, nitro, cyano, C 1-7 alkoxy, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene;
R 6 and R 9 are H;
R 7 is a C 1-4 alkoxy, optionally substituted by a C 5 heteroaryl or phenyl group;
either:
(a) R 10 is H, and R 11 is OH, OR A , where R A is C 1-4 alkyl;
(b) R 10 and R 11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or
(c) R 10 is H and R 11 is SO z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;
R″ is a C 3-12 alkylene group, which chain may be interrupted by one or more aromatic rings;
Y and Y′ are selected from O, S, and NH;
R 6′ , R 7′ , R 9′ are selected from the same groups as R 6 , R 7 and R 9 respectively and R 10′ and R 11′ are the same as R 10 and R 11 , wherein if R 11 and R 11′ are SO z M, M may represent a divalent pharmaceutically acceptable cation,
wherein the term C 3-7 heterocycyl refers to a monovalent moiety obtained by removing a hydrogen atom for a ring atom of a heterocyclic compounds which has from 3 to 7 ring atoms of which 1 to 4 are ring heteroatoms selected from N, O and S,
wherein the term C 5-10 heteroaryl refers to a monovalent moiety obtained by removing a hydrogen atom for a ring atom of a heteroaromatic compound which has from 5 to 10 ring atoms of which 1 to 4 are ring heteroatoms selected from N, O and S.